Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nascent Biologics and Catalent Pharma Solutions have signed a cancer antibody development agreement.
Subscribe to our email newsletter
As part of the agreement, Catalent will engineer a cell line expressing Nascent’s Pritumumab antibody using Catalent’s GPEx technology.
Catalent will produce purified monoclonal antibody to support Nascent’s Phase I/II human clinical trials with Pritumumab for treatment of brain cancers, such as astrocytomas and glioblastomas.
Nascent CEO Mark Glassy said: "Nascent Biologics is in the process of forming a commercial partnership for further clinical development, registration, and marketing of its Pritumumab product."